Understanding venous insufficiency and chronic edema.

Augment clinical care with effective at-home treatment to improve outcomes and reduce cost.



Fluorescence imaging illustrates lymphatic dysfunction associated with chronic venous insufficiency¹



Chronic edema.

The veins and lymphatics form one interdependent fluid-balance system. For CVI patients with chronic edema (phlebolymphedema), this venolymphatic connection means that a singular focus on repairing veins will not resolve swelling — the lymphatics must also be addressed.²

Chronic edema indicates an inadequacy or failure of lymphatic drainage.

The traditional Starling Principle (below, left) held that capillary oncotic pressure drove reabsorption of interstitial fluid into the venules, leaving approximately 10 percent to be removed by the lymphatic system. However, subsequent research has revealed the role of the endothelial glycocalyx layer in the capillary bed: there is no net venous reabsorption and interstitial fluid returns to the circulation only via the lymphatics (below, right).^{3,4}

THE REVISED STARLING PRINCIPLE

Classical model: now known to be incorrect.

Traditionally it was taught that 90% of interstitial fluid was reabsorbed by the venous system. This is now known to be incorrect.



Modern view: glycocalyx model.

Modern evidence shows the endothelial glycocalyx prevents venous reabsorption. Therefore, all chronic edema indicates an inadequacy or failure of lymphatic function.^{3,4}



CVI-related chronic edema.

CVI-related chronic edema is a two-system failure that requires early detection and comprehensive treatment.

Phlebolymphedema occurs when an excessive burden of capillary filtrate overwhelms the lymphatics, most often due to venous hypertension. Just as CVI causes microangiopathic changes in the venous system, prolonged chronic edema can permanently damage the lymphatics,⁵ paving the way for progressive infection and complications,⁶ increased office visits, and costly treatments and hospitalizations.

Compression garments and appropriate endovenous or surgical interventions can reduce venous hypertension. However, phlebolymphedema requires early detection and comprehensive lymphatic therapy to reduce buildup of protein-rich edema and thereby lower risk of infection and inflammation.⁷ Pneumatic compression devices (PCDs) can complement acute lymphatic therapy and improve patient self-care. Only the Flexitouch® Plus system has been proven to stimulate the lymphatics,⁸ improve outcomes,^{9,10} lower costs^{9,10} and improve quality of life¹¹ for phlebolymphedema patients.

> ...clinical examination is adequate for diagnosing lymphedema and that all patients with chronic venous insufficiency (C3–C6) should be treated as lymphedema patients.¹²

2022 EXPERT CONSENSUS FOR LYMPHEDEMA DIAGNOSIS AND TREATMENT:12

All patients with chronic			
venous insufficiency			
should be considered as			
lymphedema patients.			

Regular use of compression garments reduces progression of lymphedema.

Read the full consensus:

"

Pneumatic compression should be recommended for lymphedema patients.





CVI-related chronic edema (phlebolymphedema).

LYMPHATIC CHANGES ARE PRESENT IN EARLY CLINICAL STAGES OF CHRONIC VENOUS DISEASE In biopsies, patients with CVI show structural lymphatic changes, including collapsed lumens and disturbance of lumen-opening filaments, resulting in reduced function.⁵ This chart illustrates how lymphatics can be impacted at each clinical stage of the Comprehensive Classification System for Chronic Venous Disorders (CEAP).¹³

CHRONIC VENOUS DISEASE (CVD)

CLINICAL STAGE

C0 C1 C2	No Clinical SignsTelangiectasias or Reticular VeinsVaricose Veins	A healthy lymphatic system (right) allows lymph to enter and flow through lymphatic capillaries. In early stage venous disease, lymphatics are able to manage the venous filtrate overload.	CO
C3	Edema (Pitting) Edema (Non-pitting)	Lymphatics are unable to accommodate excess venous filtrate, so swelling occurs. ³ Prolonged excess venous filtrate overburdens lymphatics, resulting in protein buildup and permanent damage and/or obstruction. ³	C3
C4	C4a: Pigmentation or EczemaC4b: Lipodermatosclerosis or Atrophie BlancheC4c: Corona Phlebectatica	Exaggerated immune reactions such as stasis eczema and allergic contact dermatitis are indicative of compromised lymphatic immune function. ⁶ Dermal backflow follows hemosiderin staining. ¹ Chronic inflammation and fibrosis are indicative of a buildup of fluid and proteins that the lymphatics are unable to clear due to insufficiency or failure. Fibrosis indicates protein-rich buildup from lymphatic insufficiency, regardless of swelling. Corona phlebectatica is recognized as a leading predictor of venous ulcer with risk profile similar to other C4 skin changes.	C4
C5	Healed Venous Ulcer	Scar tissue disrupts lymphatic drainage.	C6
C6	Active Venous Ulcer	Open wound disrupts superficial lymphatics and lymph fluid leaks from the ulcers.	

LYMPHATIC INVOLVEMENT SHOWN VIA

NEAR INFRARED FLUORESCENCE LYMPHATIC IMAGING¹

LYMPHEDEMA (LE) CLINICAL STAGE



Stage 0: Latent No clinical signs.



Stage 1: Pitting Edema

Soft swelling, resolves with elevation or overnight.

Stage 2: Non-pitting Edema

Swelling with deepened skin folds and notable tissue changes such as fibrosis, scaly skin and possible hyperkeratosis; does not resolve with elevation.

Left unmanaged, lymphedema can progress to:

Stage 3: Lymphostatic Elephantiasis

Extensive and/or disfiguring fibrotic swelling, blistering and ulcerations, lymphorrhea, hyperkeratosis, papillomas and recurrent infections.

At-home treatment from Tactile Medical.

Choose Flexitouch[®] Plus — the clinically proven at-home treatment system with high patient satisfaction and compliance.¹⁴



The Flexitouch Plus is clinically proven to stimulate the lymphatic system⁸ and is backed by the most extensive body of clinical evidence of any pump on the market. And, our new ComfortEase garments have been redesigned to:

- Be easier to use
- Fit a wider range of body types
- Offer added comfort due to thinner, less bulky materials

Flexitouch mechanism of action.



The unique mechanism of action of the Flexitouch system stimulates the lymphatic system to remove excess fluid and reduce edema. The pneumatic chambers sequentially inflate and deflate for just a few seconds each, creating a gentle wave-like application of pressure to stimulate the movement of lymphatic fluid and direct it toward properly functioning areas of the body.

Clinically proven technology.

Pneumatic compression leads in patient satisfaction, perceived effectiveness and price value when compared to other treatments, including compression, manual lymphatic drainage and more. -VASCULAR PATIENT INSIGHTS SURVEY¹⁵

Our commitment to research.

Our commitment to research has resulted in dozens of peer-reviewed clinical studies and scholarly articles — more than any other pneumatic compression manufacturer. The results of two studies are highlighted here:

Evidence supporting optimal treatment of phlebolymphedema.¹⁰

A study of 1,065 patients with CVI and lymphedema (phlebolymphedema) published in the Journal of Vascular Surgery found Flexitouch use significantly reduced per-patient phlebolymphedema-related costs when compared with alternative treatment modalities (all pumps used in conjunction with conservative therapy):

69%

Reduction vs. conservative therapy alone

Reduction vs. simple lymphedema pumps

At-home Flexitouch treatment improves health outcomes and reduces costs.⁹

A study of 344 non-cancer-related lymphedema patients published in the Journal of the American Medical Association Dermatology found that lymphedema treatment utilizing the Flexitouch system resulted in long-term reductions in healthcare utilization and costs:^{9b}



"





Reduction vs. other advanced lymphedema pumps



Reduction in rate of outpatient hospital visits



Reduction in rate of lymphedema-related costs per patient

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home.

Let's work together.



Individual results may vary.

Indications/contraindications: Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device.

Caution: Federal (U.S.) law restricts this device to sale by or on the order of a licensed healthcare practitioner.

References:

- 1. Rasmussen JC, Aldrich MB, Tan IC, et al. Lymphatic transport in patients with chronic venous insufficiency and venous leg ulcers following sequential pneumatic compression. J Vasc Sura Venous and Lymphat Disord. 2016:4(1):9–17.
- 2. Partsch H, Lee BB. Phlebology and lymphology–A family affair. Phlebology. 2014; 29(10): 645–647.
- 3. Mortimer PS, Rockson SG. New developments in clinical aspects of lymphatic disease. J Clin Invest. 2014;124(3):915-21.doi:10.1172/JCI71608.
- 4. Levick JR, Michel CC. Microvascular fluid exchange and the revised Starling principle. Cardiovasc Res. 2010;87(2):198–210.
- 5. Scelsi R, Scelsi L, Cortinovis R, Poggi P. Morphological changes of dermal blood and lymphatic vessels in chronic venous insufficiency of the leg. Int Angiol. 1994;13(4):308–11.
- 6. Ruocco E, Brunetti G, Brancaccio G, Schiavo AL. Phlebolymphedema: Disregarded cause of immunocompromised district. Clin Dermatol. 2012;30(5):541-3.
- 7. Farrow W. Phlebolymphedema-a common underdiagnosed and undertreated problem in the wound care clinic. J Am Col Certif Wound Spec. 2010;2(1):14–23.
- 8. Adams KE, Rasmussen JC, Darne C, et al. Direct evidence of lymphatic function improvement after advanced pneumatic compression device treatment of lymphedema. *Biomed Opt Express*. 2010;1(1):114–125.
- 9. Karaca-Mandic P, Hirsch AT, Rockson SG, Ridner SH. The cutaneous, net clinical, and health economic benefits of advanced pneumatic compression devices in patients with lymphedema. *JAMA Dermatol.* 2015;151(11):1187–1193. The study analyzed upper and lower extremity lymphedema patients with cancer related (9a) and non-cancer related lymphedema (9b) treated with the Flexitouch System. The study evaluated use of the Flexitouch System as a tool for the treatment of lymphedema. The study documented a reduction in the rate of cellulitis episodes following use of the Flexitouch System for the treatment of lymphedema. The Flexitouch System is not used for nor intended for use to treat cellulitis.
- 10. Lerman M, Gaebler JA, Hoy S, et al. Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema. J Vasc Surg. 2019;69(2):571–80.
- 11. Blumberg SN, Berland T, Rockman C, et al. Pneumatic compression improves quality of life in patients with lower-extremity lymphedema. Ann Vasc Surg. 2016;30:40–4.
- 12. Lurie F, Malgor R, Carman T, et al. The American Venous Forum, American vein and lymphatic society and the society for vascular medicine expert opinion consensus on lymphedema diagnosis and treatment. *Phlebology: The Journal of Venous Disease*. 2022.
- 13. Lurie F, Passman M, Meisner M, et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342-352. doi:10.1016/j.jvsv.2019.12.075
- 14. Ridner SH, McMahon E, Dietrich MS, Hoy S. Home-based lymphedema treatment in patients with cancer-related lymphedema or noncancer-related lymphedema. Oncol Nurs Forum. 2008;35(4):671.
- 15. Data on file with Tactile Medical

Patient photos courtesy of Dr. Tony Gasparis or patient photo consent on file at Tactile Medical.

Tactile Medical

3701 Wayzata Blvd, Suite 300 Minneapolis, MN 55416 USA T: 612.355.5100 F: 612.355.5101 Customer Service Toll Free Tel: 833.382.2845 (833.3TACTILE) Toll Free Fax: 866.435.3949 Hours: 7 a.m. to 7 p.m. CT, Monday–Friday tactilemedical.com



Tactile Medical and Flexitouch are registered trademarks and Healing Right at Home is a trademark of Tactile Medical. ©2022 Tactile Medical. All rights reserved. 701448-001 Rev B 4/2022